SCHEMBL6715563

SCHEMBL6715563

CC(C)c1ccc(NC(=O)C(c2ccccc2)N(C(=O)O)C(C)(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
ALDH1A1 P00352 8/20 0.52
PTPN1 P18031 1/20 0.50
PTPN6 P29350 1/20 0.50
PTPN11 Q06124 1/20 0.50
TSHR P16473 1/20 0.47
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 2/20 0.45
EGFR P00533 1/20 0.45
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723623 0.90 POLB (0.51) ALDH1A1GAAMAPTATMLMNA
SCHEMBL6713979 0.90 ALDH1A1 (0.53) CRHBPCRHR2ALDH1A1TSHRGAA
SCHEMBL6716854 0.88 ALDH1A1 (0.53) ALDH1A1GAAMAPTRAB9AMAPK1
SCHEMBL6717793 0.85 KMT2A (0.50) ALDH1A1TSHRGAACYP1A2CYP3A4
SCHEMBL21987995 0.84 KLK7 (0.44) CRHBPCRHR2ALDH1A1GAACYP1A2
SCHEMBL4532143 0.83 ROCK2 (0.48) ALDH1A1GAAMAPK1LMNAPOLB
SCHEMBL6718720 0.83 KMT2A (0.48) ALDH1A1GAATP53MAPTRAB9A
SCHEMBL4519493 0.83 ROCK2 (0.48) ALDH1A1GAAMAPK1LMNAPOLB
SCHEMBL6714344 0.81 ALDH1A1 (0.56) ALDH1A1TSHRGAATP53MAPT
SCHEMBL6716822 0.80 KCNQ2 (0.56) ALDH1A1GAACYP1A2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 CRHBP 1808/4885CRHR2 1096/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.